Profile
NVIV NVO VRTX REGN SGEN MRNA
Company Name InVivo Therapeutics Holdings Corp. Novo Nordisk A/S Vertex Pharmaceuticals Incorporated Regeneron Pharmaceuticals, Inc. Seagen Inc. Moderna, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $995.92K $550.22B $102.67B $95.34B $43.15B $41.34B
Employees 0.01K 63.37K 5.40K 13.45K 3.26K 5.60K
CEO Dr. Richard M. Toselli M.D. Mr. Lars Fruergaard Jorgensen Dr. Reshma Kewalramani FASN, M.D. Dr. Leonard S. Schleifer M.D., Ph.D. Mr. David R. Epstein B.Sc., M.B.A. Mr. Stephane Bancel
Ratings
NVIV NVO VRTX REGN SGEN MRNA
Quant Rating Score 3 5 5 5 3 4
Quant Rating Neutral Strong Buy Strong Buy Strong Buy Neutral Buy
Trading
NVIV NVO VRTX REGN SGEN MRNA
Last Close $0.3207 $126.85 $397.48 $883.2 $228.74 $107.97
High 52 $1.45 $199.54 $446.08 $993.35 $228.9 $137.75
Low 52 $0.22 $87.78 $323.57 $692.45 $187.64 $69.51
Price vs. 52 Week High -77.88 % -36.43 % -10.89 % -11.09 % -0.07 % -21.62 %
Price vs. 52 Week Low 45.77 % 44.51 % 22.84 % 27.55 % 21.9 % 55.33 %
Total Return
NVIV NVO VRTX REGN SGEN MRNA
1 Month Return 0 % -1.21 % -4.91 % -8.24 % 0 % 1.32 %
3 Month Return -51.56 % 16.35 % -8.8 % -7.6 % 0 % 2.99 %
6 Month Return -65.61 % 35.67 % 11.88 % 13.93 % 6.59 % 50.15 %
9 Month Return -76.75 % -19.62 % 12.27 % 18.38 % 19.07 % -9.01 %
YTD Return -56.07 % 22.62 % -2.31 % 0.56 % 0 % 8.57 %
1 Year Return -76.17 % -24.08 % 16.66 % 10.15 % 14.37 % -18.75 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
NVIV NVO VRTX REGN SGEN MRNA
Dividend Yield Percentage (TTM) - 1.43 % - - - -
Dividend Paid and Capex Coverage Ration (TTM) -225.07 % 1.54 % 13.69 % 5.88 % -3.35 % -4.41 %
Dividend Per Share (TTM) - 1.81 % - - - -
Payout Ratio (TTM) - 37.96 % - - - -
Growth
NVIV NVO VRTX REGN SGEN MRNA
Asset Growth -13.54 % 30.35 % 25.23 % 13.23 % -1.21 % -28.74 %
Gross Profit Growth -19.62 % 32.32 % 9.25 % 6.49 % 22.93 % -85.12 %
Revenue Growth - 31.26 % 10.17 % 7.76 % 24.65 % -64.94 %
Revenue 3 Year - 90.51 % 59.87 % 56.27 % 91.84 % 2354.12 %
Revenue 5 Year - 124.2 % 218.58 % 97.36 % 215.48 % 1070.62 %
Revenue 10 Year - 66.11 % 608.27 % 509.63 % 494.04 % 6447.35 %
EBIT Growth -7.58 % 37.11 % -12.94 % -14.6 % 10.13 % -145 %
Net Income Growth -2.9 % 50.71 % 8.96 % -8.87 % 9.51 % -156.37 %
Net Income 3 Yeari Growth Per Share 99.27 % 106.79 % 34.59 % 13.92 % -764.83 % -529.35 %
Net Income 5 Yeari Growth Per Share 99.96 % 133.86 % 70.33 % 63.31 % -276.93 % -160.17 %
Net Income 10 Yeari Growth Per Share -100.12 % 98.61 % 809.6 % 811.34 % -624.16 % -2046.03 %
Operating Income Growth -7.58 % 37.11 % -12.94 % -14.6 % 10.13 % -145 %
Operating Cash Flow Growth (CFG) -18.39 % 38.06 % -14.35 % -8.39 % 9.07 % -162.6 %
Operating 3 Year CFG 99.11 % 118.29 % 9.63 % 77.63 % -148.34 % -253.42 %
Operating 5 Year CFG 99.94 % 163.51 % 174.78 % 111.31 % -195.86 % -100.11 %
Operating 10 Year CFG 99.94 % 150.92 % 5187.08 % 663.48 % -2622.09 % -4698.89 %
EPS Growth 11.38 % 52.28 % 8.33 % -8.54 % 10.81 % -158.04 %
EPS Diluted Growth 11.38 % 52.37 % 8.35 % -9.03 % 10.81 % -161.33 %
Book Value Per Share -25.12 % 29 % 25.58 % 14.4 % -9.83 % -21.18 %
Share Holder 3 Year Equity Growth Per Share -97.54 % 75.22 % 104.06 % 138.48 % 33.92 % 439.47 %
Share Holder 5 Year Equity Growth Per Share -99.82 % 121.9 % 291.14 % 199.46 % 220.81 % 92.24 %
Share Holder 10 Year Equity Growth Per Share 100.39 % 49.62 % 1030.79 % 1201.51 % 691.19 % 1519.81 %
Dividend Per Share Growth - 26.89 % - - - 59.65 %
Dividend 3 Year Growth Per Share - 64.4 % -100 % - - 3725.19 %
Dividend 5 Year Growth Per Share - 80.03 % -100 % - - -
Dividend 10 Year Growth Per Share - 95.44 % - - - -
Debt Growth -27.56 % 4.74 % 44.1 % 0.06 % -23.28 % 3.58 %
Free Cash Flow Growth -19.16 % 9.17 % -16.47 % -17.11 % 3.67 % -183.5 %
Updated On 31 Dec 2022 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Dec 2022 31 Dec 2023
Profitability
NVIV NVO VRTX REGN SGEN MRNA
Gross Profit Margin TTM - 84.6 % 87.21 % 87.87 % 75.4 % 31.49 %
Return on Assets TTM -93.73 % 26.61 % 15.92 % 11.95 % -20.64 % -25.58 %
Return on Equity TTM -72.27 % 90.49 % 22.62 % 16.07 % -28.06 % -29.87 %
Return on Capital Employed TTM -109.05 % 70.82 % 19.82 % 13.65 % -29.5 % -27.51 %
Net Income Per EBT TTM 96.31 % 79.95 % 82.64 % 94.15 % 101.53 % 119.58 %
EBT Per Ebit TTM 95.91 % 102.05 % 115.19 % 103.76 % 93.47 % 92.99 %
EBIT Per Revenue TTM - 44.16 % 38.53 % 30.85 % -34.37 % -61.88 %
Cash Flow To Debt Ratio TTM - 403.27 % 437.57 % 169.97 % -475.96 % -250.84 %
Receivables Turnover TTM - 3.09 6.31 2.31 3.64 6.34
Payables Turnover TTM 3.41 1.4 3.46 2.62 2.52 9.03
Inventory Turnover TTM - 1.12 1.71 0.62 1.07 23.23
Fixed Asset Turnover TTM - 255.34 % 679.28 % 316.35 % 471.71 % 257.71 %
Asset Turnover TTM - 73.85 % 43.42 % 39.65 % 63.3 % 37.18 %
Operating Cash Flow Per Share TTM -3.26 24.39 13.73 43.1 -2.87 -8.18
Free Cash Flow Per Share TTM -3.28 15.68 12.72 35.77 -3.73 -10.04
Cash Per Share TTM 276.28 % 677.09 % 4354.48 % 10173.36 % 657.5 % 2258.27 %
Operating Cash Flow Sales Ratio TTM - 46.89 % 35.84 % 35.02 % -23.48 % -45.52 %
Free Cash Flow Operating Cash Flow Ratio TTM 100.44 % 64.29 % 92.69 % 83.01 % 129.82 % 122.67 %
Cash Flow Coverage Ratios TTM - 403.27 % 437.57 % 169.97 % -475.96 % -250.84 %
Price To Free Cash Flows Ratio TTM -0.1 54.76 31.31 25 -61.54 -10.81
Price To Operating Cash Flows Ratio TTM -0.1 36.23 28.96 20.49 -79.67 -13.19
Price Cash Flow Ratio TTM -0.1 36.23 28.96 20.49 -79.67 -13.19
Income Statement (TTM)
NVIV NVO VRTX REGN SGEN MRNA
Revenue $0B $232.26B $9.84B $13.12B $1.96B $6.75B
Gross Profit $-0B $196.5B $8.58B $11.3B $1.55B $2.06B
Gross Profit Ratio 0% 84.6% 87.17% 86.16% 79.1% 30.52%
EBITDA $-0.01B $112.94B $3.93B $5.13B $-0.62B $-3.21B
Net Income $-0.01B $83.68B $3.62B $3.95B $-0.61B $-4.71B
EPS Diluted -6.62 18.62 13.89 34.77 -3.3 -12.34
Balance Sheet (MRQ)
NVIV NVO VRTX REGN SGEN MRNA
Long Term Debt $0B $20.53B $0.72B $2.7B $0.04B $1.22B
Total Liabilities $0B $207.93B $5.15B $7.11B $0.87B $4.57B
Total Equity $0.02B $106.56B $17.58B $25.97B $2.8B $13.85B
Total Investments $0B $17.5B $3.45B $13.51B $1.42B $4.68B
Total Debt $0B $27.01B $0.81B $2.7B $0.04B $1.24B
Total Assets $0.02B $314.49B $22.73B $33.08B $3.67B $18.43B
Cash Flow Statement (TTM)
NVIV NVO VRTX REGN SGEN MRNA
Net Income $-0.01B $83.68B $3.62B $3.95B $-0.61B $-4.71B
Inventory $0B $-7.42B $-0.32B $-0.27B $-0.23B $0.75B
Dividends Paid $0B $-31.77B $0B $0B $0B $0B
Operating Cash Flow $-0.01B $108.91B $3.54B $4.59B $-0.45B $-3.12B
Capital Expenditure $-0B $-38.9B $-0.26B $-0.93B $-0.08B $-0.71B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 1.85
ABCL AbCellera Biologics Inc. 3.855
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 3.44
ABIO ARCA biopharma, Inc. 3.4575
ABOS Acumen Pharmaceuticals, Inc. 3.175
ABSI Absci Corporation 4.74
ABUS Arbutus Biopharma Corporation 2.77
ABVC ABVC BioPharma, Inc. 1.4001
ABVX Abivax SA American Depositary Shares 15.48
ACAD ACADIA Pharmaceuticals Inc. 17.1
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 1.59
ACGN Aceragen, Inc. 0.3849
ACHL Achilles Therapeutics plc 0.7601
ACHV Achieve Life Sciences, Inc. 4.6
ACIU AC Immune SA 2.41
ACLX Arcellx, Inc. 51.01
ACRV Acrivon Therapeutics, Inc. Common Stock 10.015
ACST Acasti Pharma Inc. 2.735
ETFs With Exposure to NVIV
Ticker ETF Name Weight Percentage Price
ITOT iShares Core S&P Total U.S. Stock Market ETF 0 112.055
DFAT Dimensional U.S. Targeted Value ETF 0 52.225
Unlock